Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ursula A Matulonis

Showing results (121-130 of 215) with videos related to

Pageof 22
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumorsRichard T Penson, Don S Dizon, Stephen A Cannistra, et al.
JAMA Oncology|October 11, 2019
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical TrialJoyce F Liu, Christina Herold, Kathryn P Gray, et al.
Plos One|February 21, 2012
Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancerStefan Bentink, Benjamin Haibe-Kains, Thomas Risch, et al.
American Journal of Obstetrics and Gynecology|June 18, 2019
Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancerAllison Gockley, Alexander Melamed, Angel Cronin, et al.
Cancer|April 26, 2017
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumorsKathleen N Moore, Hossein Borghaei, David M O'Malley, et al.
Gynecologic Oncology|July 2, 2026
Toward precision prognosis: Predicting recurrence-free survival in high-grade serous ovarian cancer patients using multi-time point clinical and computed tomography radiomics dataLauren Roller, Ningxuan Zhou, Isha Atre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2023
Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II StudyNicoletta Colombo, Toon Van Gorp, Ursula A Matulonis, et al.
Gynecologic Oncology|February 22, 2020
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancerDavid M O'Malley, Ursula A Matulonis, Michael J Birrer, et al.
Gynecologic Oncology|January 7, 2025
Incorporating immune checkpoint inhibitors in epithelial ovarian cancerGiorgio Bogani, Kathleen N Moore, Isabelle Ray-Coquard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2022
Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast CancerFelipe Batalini, Niya Xiong, Nabihah Tayob, et al.
Pageof 22

Showing results (121-130 of 215) with videos related to

Sort By:
Pageof 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumorsRichard T Penson, Don S Dizon, Stephen A Cannistra, et al.
JAMA Oncology|October 11, 2019
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical TrialJoyce F Liu, Christina Herold, Kathryn P Gray, et al.
Plos One|February 21, 2012
Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancerStefan Bentink, Benjamin Haibe-Kains, Thomas Risch, et al.
American Journal of Obstetrics and Gynecology|June 18, 2019
Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancerAllison Gockley, Alexander Melamed, Angel Cronin, et al.
Cancer|April 26, 2017
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumorsKathleen N Moore, Hossein Borghaei, David M O'Malley, et al.
Gynecologic Oncology|July 2, 2026
Toward precision prognosis: Predicting recurrence-free survival in high-grade serous ovarian cancer patients using multi-time point clinical and computed tomography radiomics dataLauren Roller, Ningxuan Zhou, Isha Atre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2023
Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II StudyNicoletta Colombo, Toon Van Gorp, Ursula A Matulonis, et al.
Gynecologic Oncology|February 22, 2020
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancerDavid M O'Malley, Ursula A Matulonis, Michael J Birrer, et al.
Gynecologic Oncology|January 7, 2025
Incorporating immune checkpoint inhibitors in epithelial ovarian cancerGiorgio Bogani, Kathleen N Moore, Isabelle Ray-Coquard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2022
Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast CancerFelipe Batalini, Niya Xiong, Nabihah Tayob, et al.
Pageof 22